Autonomic effects of nebivolol versus atenolol in healthy subjects

Cardiovascular Drugs and Therapy

Volumn 18, Issue 6, 2004, Pages 469-473

  Chiladakis, John A ^a,b   Georgiopoulou, Ekaterini ^a   Alexopoulos, Dimitrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b NONE   (Greece)

Author keywords

Atenolol; Heart rate variability; Nebivolol

Indexed keywords

ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART RATE VARIABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NIGHT; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VASODILATATION; VOLUNTEER;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; ATENOLOL; AUTONOMIC NERVOUS SYSTEM; BENZOPYRANS; CHRONOBIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY, AMBULATORY; ETHANOLAMINES; FEMALE; HEART RATE; HUMANS; MALE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 16844386220     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-004-6224-0     Document Type: Article

References (13)

1. Chowdhary S, Vaile JC, Fletcher J, Ross HF, Coote JH, Townend JN. Nitric oxide and cardiac autonomic control in humans. Hypertension 2000;36:264-269.
2. Schwarz P, Diem R, Dun NJ, Fostermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 1995;77:841-848.
3. Ignarro LJ, Sisodia M, Trinh K, et al. Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide 2002;7:83-90.
4. Cockroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO dependent mechanism. J Pharmacol Exp Ther 1995;474:1067-1071.
5. Ma S, Long JP. Central noradrenergic activity and the cardiovascular effects of nitroglycerin. J Cardiovasc Pharmacol 1992;20:826-836.
6. Zanzinger J, Czachurski J, Seller H. Impaired modulation of sympathetic excitability by nitric oxide after long-term administration of organic nitrates in pigs. Circulation 1998;97:2352-2358.
7. Task Force of the European Society of Cardiology and the North American Society of Pacing Electrophysiology. Heart rate Variability: standards of measurements, physiological interpretation, and clinical use. Circulation 1996;93:1043-1065.
8. Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation 1991;81:537-547.
9. Janssens WJ, Van de Water A, Xhonneux E, Reneman RS, Van Nueten JM, Janssen PAJ. Nebivolol is devoid of intrinsic sympathomometic activity. Eur J Pharmacol 1989;159:89-95.
10. Tuck ML, Stern N, Sowers JR. Enhanced 24-h norepinephrine and rennin secretion in young patients with essential hypertension: Relation with the circadian pattern of arterial blood pressure. Am J Cardiol 1985;55:112-115.
11. Eckberg DL. Sympathovagal balance. A critical appraisal. Circulation 1997;96:3224-3232.
12. Kleiger RE, Bigger JT, Bosner MS, et al. Stability over time of variables measuring heart rate variability in normal subjects. Am J Cardiol 1991;68:626-630.
13. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation 2001;104:511-514.